Medicago, Genopole Sign Agreement For Vaccine Production In France

Medicago and Genopole have signed a partnership agreement with a plan to build a commercial facility to manufacture pandemic and seasonal influenza vaccines in France. Both the firms expect that this facility could complement France’s existing domestic influenza vaccine production infrastructure, by offering surge capacity of influenza vaccines before the first wave of a pandemic strikes.

Genopole and Medicago would work together to establish a commercial-scale facility based on Medicago’s Proficia plant-based manufacturing technology and VLP vaccine technology on Genopole’s site in Evry, France. The company said that the new facility would initially produce pandemic and seasonal influenza vaccines and could be used for a broad range of vaccines and other biodefense related products.

Andy Sheldon, president and CEO of Medicago, said: We are proud to be working with Genopole to contribute towards the strengthening of France’s health infrastructure. This agreement is in line with our strategy to export our rapid and cost-effective solution for the manufacturing of influenza vaccines to enable countries worldwide to produce their own vaccines, within their own borders.